CTIX Stock Updates 08/19/2014 07:27:10 $CTIX The million

New Post Public Reply Private Reply Replies (0) Message Board
Jake13
CTIX Stock Updates 08/19/2014 07:27:10 $CTIX
The million dollar question...will this support the rise of SP..or the typical RED day the day of PR. ..this is exciting
And here is the PR....
Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

BEVERLY, MA--(Marketwired –August 19,2014)- Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has announced the completion of enrollment in its Phase 2b trial comparing Brilacidin™ to daptomycin (Cubicin®) in patients with acute bacterial skin and skin structure infections (ABSSSI). Overall, 215 patients were randomized to one of three dosing regimens of Brilacidin (single dose 0.6mg/kg; single-dose 0.8mg/kg; 1.2mg/kg over 3 days) or 7 days of once daily daptomycin.

Brilacidin is the lead compound among a novel class of antibiotics known as defensin-mimetics. These compounds have shown great promise in preclinical and early clinical studies as potent antibiotics that can kill Staph aureus, including methicillin-resistant Staph aureus (MRSA). Moreover, given the unique mechanism of action, among other attributes, there is low, if any, potential for the development of resistance. Finally, the results of the current study may demonstrate that Brilacidin could be given as a single-dose, which provides benefits for both patients and society.

This combination of properties makes Brilacidin unique among antibiotics recently approved or in development for the treatment of MRSA. Because these other compounds come from existing classes of antibiotics, there is the potential for cross-resistance; this is not the case for Brilacidin.

"This is an important milestone for Cellceutix and for the field of infectious diseases" said Leo Ehrlich, the company's CEO. "There is no other antibiotic with these properties, which can treat infection and potentially decrease the burden of antibiotic resistance. Resistance, the antibiotic slayer. We are now in the process of manufacturing 30 kg of Brilacidin for future clinical trials which we plan for multiple forms of serious infections."

The company expects data from the trial to be available in the fourth quarter of 2014.
Have a great bday Wild, let's hope CTIX gives you $2+ for your bday today.
One thing I noticed is there seems to be more new posters showing up here. It seems like a month ago the followers of this board, was in the low 400's. I see today it is 446 followers. I agree, it looks like smart money is in here buying, but I also think we have gained new interest from Retail. Not sure how they found their way here.
Welcome to all new shareholders and followers here!
wild4ctix, HAPPY BIRTHDAY!!!



GO CTIX
If you could tell me what the root cause of this two day surge was, then I could attempt to give a decent prediction. If our first institution is here then I think we could do over a million shares and it is possible to close at $2.09 or higher. If not, then I have no clue. :>
Happy Birthday Wild one. Here's hoping Leo and company send you a present worthy of your enthusiasm. The sun arrived on time again this morning. I bet it will set on time too. CTIX has a big beautiful sunrise coming. Too early to talk about sunsets.
GOGOGOGO CTIX and Go Gamecocks!!!!!
Couple thoughts:

1) Don't think much retail participation yet. This won't really heat up until Smart Money passes the wand.

2) Could be R&R conference may set limits to selling.

3) I'm still not ruling out that Smart Money may take another break. They have been pretty cagey. Large sellers taking advantage of the increased liquidity may overplay their hand and create too much supply.

4) Regardless, I don't see this run as being over. It may take a break or two going forward.

5) Overall, Smart Money usually moves on information. Information, often not obvious to the general market. Once this information becomes clear to all; then, Smart Money reaps in their profit as price reflects the information. This is key, because timing is a question, but direction is less so. Just follow the Smart Money.
Prediction for SP & Vol ?
Good Morning, World Good Morning, CTIX!

Happy Birthday! wild4ctix!
Happy Birthday Wild! Wishing you a great day!
Go CTIX!
Great post INH! Also, excellent call on picking up on all the stealth buying the past several weeks preceding this move. The volume the past 3 days: 79k, 432k on Friday, and 804k yesterday.
It will be very interesting to see what today brings.
Does volume surge yet again over a million shares, or does volume taper off?
Go CTIX!
Go CTIX!
I do my part as a faithful long looking for great accomplishments from LEO and Menon.
I believe that we will get updates by R and R for all 3 agents currently in clinical trials

Some large group or groups are buying in now because they believe the data will propel the
pps.
Volume upswings always precede news and I hope for the best.

Glad to see Georgejji posting here very frequently because his moniker represents the interests of large players(IMO).

when George arrives volume usually perks up and then news follows!!!!
Ask @ $3.34 ... Maybe in a few weeks
Poor critters. If Dr. Menon can formulate an aphrodisiac these creatures may not go extinct along with tigers and all the other animals supposedly killed for that reason alone.
Wildman Happy Birthday. My wish for you today is that you get an unbelievable answer from Leo. If not that, go to the twinkle!

All the best.

and yes, GO CTIX


Yes, and a big CTIX happy birthday Wild.! Now I can go to sleep and GO CTIX!!!
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Samuel Oschin Air & Space Center Takes Flight This Fall

Updated Category News Views 30

The Grand Unveiling: November Highlights Look at this: space nerds, dreamers, and just about anybody with a heartbeat and a sense of wonder should circle November 13, 2026, like a kid with a candy store gift card. That's when the California Science Center throws open the doors to the Samuel Oschin Air and Space Center. You might as well slap a 'world's first' sticker on...

Continue Reading
Software Updates Costly: UX Not the Biggest Culprit

Updated Category News Views 80

Breaking Updates Trump UX Changes Here's the real scoop: software updates that break functionality are setting companies back more than those user experience (UX) tweaks that folks gripe about but usually muddle through. According to a recent LITSLINK study, even three figures that supposedly quantify UX losses turn out to be questionable at best. Real-world Disasters:...

Continue Reading
Multiplier's Data Signals Global Hiring Evolution

Updated Category News Views 58

Shaking Up the Global Hiring Playbook You think you know how hiring works globally? Think again. Based on data from a whopping 38,000 cross-border hires, Multiplier's latest Talent Trends has spilled some hot new beans on how companies are rethinking their talent acquisition strategies. This isn’t just some thumb-twiddling speculation either—it’s grounded in real...

Continue Reading
York Space Systems Faces Turbulence Amid Investor Lawsuit

Updated Category News Views 46

York's Shaky Strategy Under the Microscope How do you go from sky-high ambitions to a grinding halt in a matter of weeks? This ain’t your typical Wall Street plot twist—it involves York Space Systems, or NYSE:YSS. These guys promised dominance in the Space Development Agency’s Transport Layer program, only to have their shooting star come crashing down. And now,...

Continue Reading
Tribal Tech Triumph: ILINX Boosts Proposal Efficiency

Updated Category News Views 72

A New Era for Tribal Operations Well, here's a headline that might've slipped under your radar, but it’s got some serious implications. Over in Olympia, Washington, ImageSource, Inc., the brains behind the ILINX platform, just scored a home run with an automated system for crafting Tribal Indirect Cost Rate Proposals (ICRPs). This ain't just gadget talk; this is a...

Continue Reading
2026 Data Integration Stars: User Sentiments Revealed

Updated Category News Views 18

Users Crown Data Integration Champions Right out of the gate, let's make one thing clear: when you're picking a data integration solution, you're essentially hitching your wagon to a vendor. This partnership, like any, can make or break your operations, and no one knows this better than the folks who've been through the trenches. Enter Infotech's 2026 Emotional Footprint...

Continue Reading
Greentown Labs Builds Momentum in Climate Innovation

Updated Category News Views 55

Paving the Way for Climate-Tech Pioneers Ah, Massachusetts—where the perfect storm of bright minds and groundbreaking innovation is brewing. It's not all just Harvard and MIT. It's programs like Greentown Labs' First Valley Fellowship stirring the pot, ushering in a new era of climate and energy startups. We're talking a robust second year for the Fellowship, where...

Continue Reading
CapCut Leads 2026 AI Image Tools for Creatives

Updated Category News Views 137

CapCut Emerges as a Go-To in AI Imagery There's no better feeling than striking gold in a flooded market. CapCut's got folks buzzing in 2026 for its top-tier AI image creation tools, according to Expert Consumers' latest rankings. On the surface, it might just seem like another tech gimmick, but dig a bit deeper, and you'll see why it's a game changer. From adland to...

Continue Reading
Step into Fear: Dead by Daylight in Moreno Valley

Updated Category News Views 8

Immersive Horror in Moreno Valley Walking straight into the fog of your nightmares isn't for the faint-hearted, but that's the kind of thrill the Moreno Valley Museum & ArtSpace is serving up with its new Dead by Daylight Immersive Experience. Kicking off just in time for Halloween on October 30, this isn't your average stroll in a museum—it's a heart-pounding,...

Continue Reading
Shareholder Lawsuit Targets Anavex Amid Falling Stock

Updated Category News Views 76

Anavex Under Fire: Investor Rights at the Forefront Another day, another lawsuit makin' waves in that fragile sea called the stock market. This time, it's Anavex Life Sciences Corp. (NASDAQ: AVXL) getting dunked in the soup for allegedly misleading their investors, leaving a bunch of folks wringing their hands and wallets. What's the Beef with Anavex? We've got a class...

Continue Reading

Top 5 Most Recently Viewed Articles

YY Inc's Profile Amidst Changing Streaming and Ad Markets

Updated Category News Views 237

YY Inc Adjusts Strategy Amidst Market Changes BofA Securities has recently reassessed the stock position of YY Inc (NASDAQ: YY), raising its price target to $36.00 from $35.00 while keeping a Neutral rating. This evaluation follows an in-depth look into the company's financial performance for the second half of the year, where growth prospects seem to showcase both...

Continue Reading
Collaboration Between Azenta and Form Bio to Transform Gene Therapy

Updated Category News Views 205

Strategic Partnership for AAV Gene Therapy Advancement In a significant push towards revolutionizing gene therapy, Azenta, Inc. (Nasdaq: AZTA) has partnered with Form Bio to enhance the development of adeno-associated virus (AAV) gene therapies. This collaboration aims to streamline the entire process of gene therapy development, ultimately providing safer and more...

Continue Reading
Dashlane Enhances Partner Program with New Incentives for Growth

Updated Category News Views 206

Dashlane Enhances Partner Program with New Incentives for Growth - New points-based program model equips and rewards resellers to expedite adoption of Dashlane Omnix™ - - Dashlane also appoints security industry veteran Tom Laffaye to lead its burgeoning channel business - Credential security leader Dashlane is excited to unveil significant enhancements to its Partner...

Continue Reading
Top Dividend Stocks Poised for Growth and Income Opportunities

Updated Category News Views 76

Introduction to High-Yield Dividend Stocks Investors are constantly seeking stocks that provide both a reliable income through dividends and significant growth potential. In today's economic environment, such opportunities are increasingly desirable. Identifying high-quality dividend-paying stocks can be the key for those looking to maximize returns. This article will...

Continue Reading
European Wax Center, Inc. Financial Report Update: Q2 2025 Insights

Updated Category News Views 113

Exciting Announcement from European Wax Center, Inc. European Wax Center, Inc. (EWCZ) is a frontrunner in the waxing services industry across the United States. The company is gearing up to share its financial performance for the second quarter of fiscal year 2025. This eagerly awaited announcement will occur on a Wednesday morning, prior to the market opening. The...

Continue Reading